New Approaches to patients with Lymphoma and (CLL) Chronic Lymphocytic Leukemia

Hello and thank you for joining me here at the American Society of Clinical Oncology meeting 2016 in Chicago. My name is Srdan Verstovsek. I'm the Professor in the Leukemia Department at MD Anderson Cancer Center in Houston, Texas.

I'm going to review briefly the highlights of the CLL and Lymphoma sections that were presented here at the meeting with several reports deserving mention. The first one that I'd like to talk about is venetoclax, which was tested in relapsed refractory CLL patients after ibrutinib or idelalisib.